Revance Therapeutics, Inc.

NasdaqGM:RVNC Stock Report

Market Cap: US$609.0m

Revance Therapeutics Valuation

Is RVNC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RVNC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: RVNC ($5.78) is trading below our estimate of fair value ($91.8)

Significantly Below Fair Value: RVNC is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for RVNC?

Other financial metrics that can be useful for relative valuation.

RVNC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.5x
Enterprise Value/EBITDA-4.5x
PEG Ration/a

Price to Sales Ratio vs Peers

How does RVNC's PS Ratio compare to its peers?

The above table shows the PS ratio for RVNC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.3x
XERS Xeris Biopharma Holdings
2.8x15.5%US$497.7m
ESPR Esperion Therapeutics
1.5x30.7%US$433.7m
SNDL SNDL
0.8x7.2%US$546.3m
ELTP Elite Pharmaceuticals
8xn/aUS$534.0m
RVNC Revance Therapeutics
2.4x22.4%US$609.0m

Price-To-Sales vs Peers: RVNC is good value based on its Price-To-Sales Ratio (2.4x) compared to the peer average (3.3x).


Price to Earnings Ratio vs Industry

How does RVNC's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a23.6%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a23.6%
n/an/an/a
No more companies

Price-To-Sales vs Industry: RVNC is good value based on its Price-To-Sales Ratio (2.4x) compared to the US Pharmaceuticals industry average (2.9x).


Price to Sales Ratio vs Fair Ratio

What is RVNC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RVNC PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.4x
Fair PS Ratio5.6x

Price-To-Sales vs Fair Ratio: RVNC is good value based on its Price-To-Sales Ratio (2.4x) compared to the estimated Fair Price-To-Sales Ratio (5.6x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst RVNC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$5.78
US$9.23
+59.6%
69.9%US$25.00US$6.00n/a7
Nov ’25US$5.80
US$9.23
+59.1%
69.9%US$25.00US$6.00n/a7
Oct ’25US$5.20
US$9.23
+77.4%
69.9%US$25.00US$6.00n/a7
Sep ’25US$6.57
US$9.65
+46.9%
66.1%US$25.00US$6.00n/a7
Aug ’25US$3.37
US$13.50
+300.6%
46.6%US$25.00US$6.00n/a12
Jul ’25US$2.57
US$13.50
+425.3%
46.6%US$25.00US$6.00n/a12
Jun ’25US$2.84
US$13.50
+375.4%
46.6%US$25.00US$6.00n/a12
May ’25US$3.80
US$16.33
+330.4%
51.5%US$32.00US$6.00n/a12
Apr ’25US$4.73
US$16.33
+245.3%
51.5%US$32.00US$6.00n/a12
Mar ’25US$6.98
US$16.33
+134.0%
51.5%US$32.00US$6.00n/a12
Feb ’25US$5.15
US$20.08
+290.0%
62.4%US$46.00US$8.00n/a12
Jan ’25US$8.79
US$26.92
+206.2%
45.4%US$46.00US$9.00n/a12
Dec ’24US$7.24
US$26.92
+271.8%
45.4%US$46.00US$9.00n/a12
Nov ’24US$7.93
US$35.83
+351.9%
36.6%US$65.00US$12.00US$5.8012
Oct ’24US$11.47
US$37.33
+225.5%
31.0%US$65.00US$15.00US$5.2012
Sep ’24US$18.16
US$39.83
+119.3%
27.6%US$65.00US$20.00US$6.5712
Aug ’24US$23.04
US$40.67
+76.5%
26.8%US$65.00US$21.00US$3.3712
Jul ’24US$25.31
US$40.58
+60.3%
27.0%US$65.00US$21.00US$2.5712
Jun ’24US$30.41
US$39.62
+30.3%
27.7%US$65.00US$21.00US$2.8413
May ’24US$32.29
US$37.38
+15.8%
27.5%US$65.00US$20.00US$3.8013
Apr ’24US$32.21
US$37.38
+16.1%
27.5%US$65.00US$20.00US$4.7313
Mar ’24US$32.25
US$36.54
+13.3%
30.2%US$65.00US$20.00US$6.9813
Feb ’24US$34.38
US$35.46
+3.1%
30.4%US$65.00US$20.00US$5.1513
Jan ’24US$18.46
US$33.38
+80.8%
32.6%US$65.00US$19.00US$8.7913
Dec ’23US$21.76
US$34.58
+58.9%
30.2%US$65.00US$22.00US$7.2412
Nov ’23US$22.46
US$34.42
+53.2%
29.3%US$65.00US$24.00US$7.9312

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies